Skip to content
Relatix Health

Relatix Health

Radically different

  • Participate
    • Start here
  • Services
    • Tests to participate in
  • Resources
  • About
    • Our Vision – A radically different future
    • Our mission – personalised lifelong support
    • News
    • FAQ
    • Contact
    • Trust and Privacy
    • Support us
  • Log in / Sign up
Posted on June 12, 2026 by admin

Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar Depression

Conditions: Treatment Resistant Bipolar Depression

Interventions: Drug: KET-AD; Other: Placebo

Sponsors: Neurocentrx Pharma Pty Ltd

Not yet recruiting
CategoriesClinicalTrials.gov TagsBiopharma, Bipolar, Depression, Mood and emotional regulation, News Approved

Post navigation

Previous PostPrevious An Investigator-Initiated, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Adjunctive Effect of CreNeuroS™ CNS Fish Oil Plus Softgels in Patients With Major Depressive Disorder Receiving Escitalopram.
Next PostNext Health-Related Social Needs Food Boxes Delivery Program
Relatix Health

Relatix Health helps people understand their minds, explore relevant support and take part in research on their own terms. We connect lived experience with responsible research while protecting privacy, dignity and choice.

For researchers, clinicians and organisations, visit our sister site, Relatix Bio.

Take part

Start here Participate Tests to participate in Log in or sign up

Find support

Resources Services FAQ I need help now

Our commitments

Our Vision Our Mission Trust and Privacy

About

About us News Support us Contact

© 2026 Relatix Health. All rights reserved.